Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is based in New Haven, Connecticut.

Trevi Therapeutics Inc.

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Trevi Therapeutics today and set a price target of $18.00. Samimy covers the Heal...

Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), SAB Bio...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TRVI	$13.07	-0.23%	759.80K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TRVI	$13.07	-0.2%	759.80K
3
4
5
6

TRVI

TRVI

Dividend Overview

Get Trevi Therapeutics Inc. Data in Excel

Get Trevi Therapeutics Inc. Data in Excel